Profile

AgPlus Diagnostics

AgPlus Diagnostics has developed a diagnostic platform technology based on research conducted at the UK’s National Physical Laboratory (NPL).

AgPlus’ platform technology combines novel electrochemistry and metallic nanoparticles signalling with diagnostic immunoassays to provide high sensitivity and fully quantitative analyte detection. The AgPlus ADVANTAGE handheld portable reader and single-use test cartridge are expected to be used across multiple applications and sectors, critically where fast cost-effective diagnostic results will enable users to make decisions, with confidence, in minutes, not hours or days.

Status current

Associated Fund Rainbow Seed Fund

Sector Medical / Biotechnology

Website www.agplusdiagnostics.com/

Associated Team Members

Relevant News

Rainbow Seed Fund Invests in AgPlus Diagnostics

AgPlus’ handheld electrochemical reader to deliver the next generation of rapid diagnostics Rainbow Seed Fund,…

read more

Fiona Marshall to lead AgPlus Diagnostics

AgPlus Diagnostics is delighted to announce the appointment of Fiona Marshall as CEO starting...

read more

AstraZeneca and AgPlus present clinical data at ERS 2017

AstraZeneca and AgPlus Diagnostics present clinical data from a novel, 10 minute, electrochemical point...

read more

AgPlus Diagnostics is Awarded Innovate UK Funding

AgPlus Diagnostics is Awarded Innovate UK Funding 13th June, 2017 – Bedford, UK. AgPlus Diagnostics, the...

read more

More Companies in Medical / Biotechnology